ArticleJAMA oncology2019

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

Shaveta Vinayak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.